News
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
BioNxt Solutions Inc. announces non-brokered private placement of units at $0.33 per Unit with maximum gross proceeds of $2,000,000. Offering includes common shares and purchase warrants -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
BioNxt Solutions Inc. announces amendment of terms for unsecured convertible debentures, extending maturity dates and issuing common share purchase warrants. For further details, visit bionxt.com -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
BioNxt Solutions Inc. announces advancement of Semaglutide oral dissolvable film program into active pharmaceutical development phase, targeting growing GLP-1 market. Company leverages expertise in drug delivery systems for chronic diseases -
